Drugs Flashcards
Drug misuse
any drug taking that causes physiological or mental harm
Tolerance
reduction in effect of a drug with repeated administraion (metabolism, receptors-number affinity, efficacy), adaptive or maladaptive
Drug dependence
withdrawal symptoms alleviated by further drug use
NSAID
non steroidal anti-inflammatory drug
Nociceptors
sensitisation nerves
COX
cyclo oxygenase - archidonic acid ->PL/PG, COX1 (PGE1 , PGE2, PGI2) protect against ulcers, COX2 inducible isoform-less GI side effects
PG
phospholipids -> prostaglandins
Opioids
Opioids - drugs that act on opioid receptors in CNS, endogenous opioids=endorphines, analgesia, sedation, respiratory depression, nausea, constipation,
Opioid receptors
nociceptor signals at sensory neuron termini (Gi), u and S and k.
Cannabinoids
CB1 gi receptors, THC
Migraines
severe headache, hypersensitivity, nausea, aura, episodic or chronic. Trigeminivascular (trigeminal sensory nerve, innervate meningal blood vessels)
Triptans
oral, subcutaneous, intranasally. Slective agonist for 5HT1B/1D (Gi) receptors in cranial blood vessels -> vasoconstriction -> decrease neurotransmitter release
Ditans
5HT1F - CNS + trigeminovascular system. Avoids 1B side effects. Gi-inhibition of presynaptic release and post signalling
CGRP
neuropeptide in trigeminal neurons. Reduce release for pain transmission= CGRP antagonist or antibodies that bind to peptide (migraines)
Diabetes mellitus
insulin deficiency (type 1), insulin resistance (type 2) -> stroke, loss of feet, skin, high bp. Gluocse monitors, check ups, medications
Insulin
produced by B cells of islets of langerhans in pancreas, tyrosine kinase receptors in liver, adipose and skeletal muscle
Glucagon-like peptide-1 (GLP-1) receptor agonists
incretin hormone (Gs), enhances glucose-mediated insulin secretion, peptide drugs with different half lives, subcutaneous. control food intake
Dipeptidyl peptidase 4 (DDP-4)
cleaves dipeptide from N terminal of GLP1 and GIP incretin, orally
Obesity
can lead to cancer, atherosclerosis, socioeconomic. Genetics, sedentary lifestyle, calories, environmental obesogens
Obesity pharmacology
block nutrient absorption, neuroactive compounds->appetite centres, block natural endogenous hormones
Amylin receptor agonists
37 aa peptide hormone produced by pancreatic b cells ->blood glucose, Gas receptors in brain.
Cardiovascular disease
(atherosclerosis, thrombosis, haemorrhage) ischaemic heart disease-blood clot in coronary arteries (angina-fatty material in artery/heart attack)
Hypertension
high blood pressure, increases risk. Below 140/90 = normal, 160/100 = treatment. -> cardiac hypertrophy, arrythmia, heart attack
Hypertension drugs
diuretics, b-blockers, calcium channel blockers, ACE inhibitors, a1 blockers (long term controlled by kidneys (RAA system))
B-blockers
block B1 in heart, decrease heart rate and force of contraction, only when sympathetic system activated.
a blockers
non specific- symp+CNS effects (a2 NA release), a1 blockers- reduced cardiovascular resistance, not first choice